New cancer cocktail aims to rev up immune system against tumors

NCT ID NCT05651022

Ongoing Disease control Sponsor: Indaptus Therapeutics, Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called DECOY20, which is designed to wake up the immune system to fight cancer. It is being tested alone or with another drug (tislelizumab) in 120 adults with advanced solid tumors like liver, lung, or colorectal cancer. The main goals are to check safety, find the right dose, and see if the treatment can control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DECOY20 (a cancer immunotherapy that activates the immune system) and tislelizumab (a drug that helps immune cells attack cancer)
What this could lead to: If it works, this could point toward a new treatment option for several advanced cancers that are hard to treat.
What could go wrong: This is an early phase 1/2 trial with only 120 people, so it is mainly checking safety and dosing. The treatment may not shrink tumors or could cause side effects like immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma colorectal neoplasm head and neck carcinoma head and neck squamous cell carcinoma hepatocellular carcinoma neoplasm non-small cell lung carcinoma pancreatic adenocarcinoma urethra transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CRC (COLORECTAL CANCER) HCC - HEPATOCELLULAR CARCINOMA MSI-H CANCER NSCLC (NON-SMALL CELL LUNG CANCER) PANCREATIC ADENOCARCINOMA SOLID TUMOR, ADULT SQUAMOUS CELL CANCER OF THE HEAD AND NECK UC (UROTHELIAL CANCER)

Contacts and locations

Locations

Atlantic Health System

Morristown, New Jersey, 07960, United States
Cleveland Clinic Taussig Cancer Center

Cleveland, Ohio, 44195, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Gabrail Cancer & Research Center

Canton, Ohio, 44718, United States
Hoag Memorial Hospital Presbyterian

Newport Beach, California, 92663, United States
Prisma Health Cancer Institute-ITOR

Greenville, South Carolina, 29605, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14263, United States
The Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
UH Seidman Cancer Center

Cleveland, Ohio, 44106, United States
University of Southern California- Norris Cancer Center

Los Angeles, California, 90033, United States
Washington University, Siteman Cancer Center

St Louis, Missouri, 63108, United States
Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.